title: Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission.
abstract: To evaluate the prognostic impact of monosomal karyotype on post-remission outcome in acute myeloid leukemia, we retrospectively analyzed 2,099 patients who had achieved complete remission. Monosomal karyotype was noted in 73 patients (4%). Of these, the probability of overall survival from first complete remission was 14% at four years, which was significantly lower than that reported in patients without monosomal karyotype, primarily due to a high relapse rate (86%). Monosomal karyotype remained significantly associated with worse overall survival among patients with unfavorable cytogenetics or complex karyotype, and even in patients who underwent allogeneic hematopoietic cell transplantation during first complete remission. These findings confirm that monosomal karyotype has a significantly adverse effect on post-remission outcome in patients with acute myeloid leukemia treated with and without allogeneic hematopoietic cell transplantation in first complete remission, emphasizing the need for the development of alternative therapies for this patient population.
authors.affiliation: 1Department of Hematology, Fujita Health University, Aichi, Japan.
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Yanada
authors.forename: Saiko
authors.initials: S
authors.lastname: Kurosawa
authors.forename: Takuhiro
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Takuya
authors.initials: T
authors.lastname: Yamashita
authors.forename: Yukiyoshi
authors.initials: Y
authors.lastname: Moriuchi
authors.forename: Hiroatsu
authors.initials: H
authors.lastname: Ago
authors.forename: Jin
authors.initials: J
authors.lastname: Takeuchi
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Nakamae
authors.forename: Jun
authors.initials: J
authors.lastname: Taguchi
authors.forename: Toru
authors.initials: T
authors.lastname: Sakura
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Takamatsu
authors.forename: Fusako
authors.initials: F
authors.lastname: Waki
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yokoyama
authors.forename: Masato
authors.initials: M
authors.lastname: Watanabe
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Emi
authors.forename: Takahiro
authors.initials: T
authors.lastname: Fukuda
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009006:Monosomy / Q000175:diagnosis / Q000235:genetics*; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents